A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm

Autor: Thomas R. Hedges, John Fezza, Amit Verma, Julie A. Woodward, Daniel D. Truong, John Burns
Rok vydání: 2016
Předmět:
Male
Time Factors
Blepharospasm
030230 surgery
Severity of Illness Index
Disability Evaluation
030207 dermatology & venereal diseases
0302 clinical medicine
Medicine
Cervical dystonia
Botulinum Toxins
Type A
Aged
80 and over
Botox
IncobotulinumtoxinA
AbobotulinumtoxinA
Middle Aged
Treatment efficacy
Treatment Outcome
Neuromuscular Agents
Neurology
Patient Satisfaction
Female
medicine.symptom
Psychology
Adult
Automobile Driving
medicine.medical_specialty
Clinical Neurology
Survey result
Dysport
Drug Administration Schedule
03 medical and health sciences
Rating scale
Internal medicine
OnabotulinumtoxinA
Humans
Xeomin
Aged
Botulinum Neurotoxin Type A
business.industry
medicine.disease
Dermatology
Cross-Sectional Studies
Reading
Time course
030221 ophthalmology & optometry
Physical therapy
Neurology (clinical)
Geriatrics and Gerontology
business
030217 neurology & neurosurgery
Botulinum toxin type
Zdroj: Parkinsonism & Related Disorders. 22:e138
ISSN: 1353-8020
Popis: To characterize satisfaction with current standard-of-care botulinum neurotoxin type A (BoNT/A) treatment for blepharospasm, we performed a cross-sectional, structured survey in subjects with blepharospasm who had received ≥2 BoNT/A cycles. Subjects were interviewed immediately before re-injection to evaluate treatment satisfaction, time course of treatment effects, preferred injection intervals, Jankovic Rating Scale (JRS), and Blepharospasm Disability Index (BSDI).Subjects’ (n=114) last treatment was onabotulinumtoxinA (n=78), incobotulinumtoxinA (n=35), or abobotulinumtoxinA (n=1). The most frequent injection interval was 12weeks (46.5% subjects); 30.7% had an interval >12weeks. The main rationale for interval choice was “to maintain treatment efficacy” (44.7%). However, 36.6% reported that treatment effects usually declined within 8weeks; 69.6% within 10weeks. JRS and BSDI scores indicated re-emergence of symptoms before re-injection, with 70.2% and 73.7% of subjects reporting difficulties to drive and read, respectively. Overall, treatment satisfaction was high, but declined at the end of the cycle. Many subjects (52.3%) would prefer an injection interval of
Databáze: OpenAIRE
Externí odkaz: